Dataset Information

SLC45A2 drives prostate cancer progression through tumor promotion and immune suppression.

ABSTRACT:

SUBMITTER: Tang R

PROVIDER: S-EPMC12820069 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

SLC45A2 drives prostate cancer progression through tumor promotion and immune suppression.

Tang Run R Wang Cheng C Zhu Yingxiang Y Liu Kai K Wu Zeming Z

Scientific reports 20251215 1

Prostate adenocarcinoma (PRAD) remains a leading cause of cancer-related mortality in men, highlighting an urgent need to identify novel prognostic biomarkers and therapeutic targets. While the role of solute carrier family genes in tumorigenesis has become increasingly well-defined, the function of the transmembrane transporter SLC45A2 in PRAD progression and immune regulation remains unclear. Transcriptomic data from 499 PRAD tumors and 52 normal tissues in the TCGA-PRAD database were integrat ...[more]

PMID: 41398365

Similar Datasets

Project description:Prostate cancer remains a leading cause of cancer-related mortality in men, with metastatic cases presenting significant therapeutic challenges due to genetic alterations that drive disease progression and immune evasion. While localized prostate cancer generally has favorable outcomes, metastatic disease is associated with much poorer survival rates. This study investigates the role of specific tumor-associated senescent non-classical monocytes (NC-Mo) in MYC amplification and PTEN deletion-mediated lethal prostate cancer progression, focusing on tumor-host immune interactions. Key genetic alterations, such as MYC amplification and PTEN deletion, lead to tumor cell apoptosis via mitochondrial Complex I dysfunction, driven by metabolic reprogramming characterized by increased glycolysis and arginine biosynthesis. A specific subtype of Ly6cLowCD43LowCXCR2+ NC-Mo is activated by the phagocytosis of apoptotic tumor cells and damage-associated molecular patterns (DAMPs) through TLR4 activation, promoting their differentiation into a senescent phenotype.TLR4 activation further induces NC-Mo to secrete TNF-α, which stimulates intra-tumor endothelial cells to produce G-CSF, circulating to the bone marrow and promoting the transition of classical monocytes into NC-Mo. Once senescent, NC-Mo secrete more TGF-β1, which enhances CXCL5 secretion from tumor cells, mainly via the AKT/PI3K pathway, creating a feedback loop that recruits more peripheral NC-Mo into the tumor microenvironment (TME). Additionally, IL-18 secreted by senescent NC-Mo suppresses T cells and NK cells, weakening both adaptive and innate immune responses in the TME. Targeting NC-Mo and key pathways, such as TLR4, CXCL5-CXCR2, and IL-18-IL18R, reduce immune suppression and inhibit tumor progression. These findings provide insights into how MYC/PTEN dysfunction accelerates prostate cancer progression through specific tumor-associated senescent NC-Mo, offering novel therapeutic opportunities.

Dataset Information

SLC45A2 drives prostate cancer progression through tumor promotion and immune suppression.

Publications

SLC45A2 drives prostate cancer progression through tumor promotion and immune suppression.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets